P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand

Benzer Materyaller

• Safety and reactogenicity of canarypox ALVAC-HIV (vCP1521) and HIV-1 gp120 AIDSVAX B/E vaccination in an efficacy trial in Thailand.
  Yazar:: Punnee Pitisuttithum, ve diğerleri
  Baskı/Yayın Bilgisi: (2011-01-01)
• ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone
  Yazar:: Margaret C. Costanzo, ve diğerleri
  Baskı/Yayın Bilgisi: (2023-05-01)
• OA04-06 LB. Post-infection cellular immune responses in recipients following ALVAC-HIV® + AIDSVAX® B/E prime-boost vaccination in the Thai Phase III Trial
  Yazar:: Chiu J, ve diğerleri
  Baskı/Yayın Bilgisi: (2009-10-01)
• Ex Vivo Evaluation of Mucosal Responses to Vaccination with ALVAC and AIDSVAX of Non-Human Primates
  Yazar:: Carolina Herrera, ve diğerleri
  Baskı/Yayın Bilgisi: (2022-01-01)
• P14-05. Recruitment, retention and participation impact events among women participating in phase III community trial in Thailand
  Yazar:: Benenson MW, ve diğerleri
  Baskı/Yayın Bilgisi: (2009-10-01)